RTC
FOLD

Riverview Trust Company’s Amicus Therapeutics FOLD Stock Holding History

Riverview Trust Company’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-55
Closed -$518 – 688
2024
Q4 		$518 Buy
+55
New +$572 ﹤0.01% 786

Other funds holding FOLD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Riverview Trust Company's FOLD Position: Q1 2025 in Review

Riverview Trust Company sold out of Amicus Therapeutics (FOLD) in Q1 2025, closing a stake of 55 shares — an estimated $518 sold.

Riverview Trust Company first reported a position in FOLD in Q4 2024 and held it in 1 quarter. The position peaked at $518 in Q4 2024. 286 funds tracked by Wall St. Rank hold FOLD as of Q1 2025.

  • Riverview Trust Company reported no remaining Amicus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Riverview Trust Company sold 55 Amicus Therapeutics shares in Q1 2025, an estimated $518.
  • Riverview Trust Company first reported a position in Amicus Therapeutics in Q4 2024 and held it in 1 quarter.
  • Riverview Trust Company's Amicus Therapeutics position peaked at $518 in Q4 2024.
  • 286 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2025.

Based on Riverview Trust Company's 13F filing for Q1 2025, filed 11 Apr 2025.